Core Viewpoint - Dalian Shengya Tourism Holdings Co., Ltd. has approved the "2025 Restricted Stock Incentive Plan (Draft)" and its summary during the board and supervisory meetings held on July 26, 2025, and has publicly disclosed the list of initial incentive recipients [1][7]. Disclosure Situation - The company published the list of initial incentive recipients on August 19, 2025, through internal bulletin boards and the OA system, with the public disclosure period lasting until August 28, 2025 [1][7]. Verification Situation - The supervisory board verified the list of initial incentive recipients, including their identification documents, employment contracts with the company and its subsidiaries, and their positions within the company [3][9]. Verification Opinions - The supervisory board confirmed that the individuals listed as initial incentive recipients meet the qualifications and conditions set forth in relevant laws and regulations, including the Company Law and the Securities Law [4][10]. - None of the initial incentive recipients fall under the disqualifications outlined in Article 8 of the Management Measures, such as being deemed inappropriate candidates by the stock exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months [5][11]. - The initial incentive recipients are all directors, senior management, middle management, and key employees of the company and its subsidiaries, excluding independent directors, supervisors, and shareholders holding more than 5% of the company's shares [6][12]. - The basic information regarding the initial incentive recipients is accurate, with no falsehoods or significant omissions [6][12].

Core Viewpoint - Anqihome Co., Ltd. is repurchasing and canceling a portion of its restricted stock due to the departure and job transfers of certain incentive recipients [1][2]. Group 1: Repurchase and Cancellation Details - The company held its 10th Board of Directors' fourth meeting on July 24, 2025, where it approved the repurchase and cancellation of 80,000 shares of restricted stock from four incentive recipients who no longer meet the incentive conditions [2]. - The repurchase is based on the company's 2024 Restricted Stock Incentive Plan and follows the relevant regulations [2]. - After the cancellation, the remaining restricted stock will total 10,908,000 shares [2]. Group 2: Legal and Compliance Aspects - A legal opinion was issued confirming that the repurchase and cancellation have obtained necessary approvals and have fulfilled information disclosure obligations [3]. - The public notice period for creditors has been completed without any claims for debt repayment or guarantees [2][3]. - The company is required to complete subsequent legal procedures and continue fulfilling its information disclosure obligations [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600526 证券简称：菲达环保 公告编号：临2025-044 浙江菲达环保科技股份有限公司 股权激励限制性股票回购注销实施公告 一、本次限制性股票回购注销的决策与信息披露 2025年7月21日，公司第九届董事会第十四次会议和第九届监事会第十一次会议审议通过了《关于回购 注销2023年限制性股票激励计划中部分激励对象已获授但尚未解除限售的限制性股票的议案》。具体内 容详见公司于2025年7月22日在上海证券交易所网站（www.sse.com.cn）和指定信息披露媒体披露的 《浙江菲达环保科技股份有限公司关于回购注销部分限制性股票及调整回购价格的公告》（公告编号： 临2025-034）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 回购注销原因 1、发生异动情形。浙江菲达环保科技股份有限公司（以下简称公司或菲达环保）2023年限制性股票激 励计划首次授予的7名激励对象因岗位调动或已离职不再具备激励对象资格，根据公司《2023年限制性 股票激励计划 ...

Core Points - The company approved the 2024 restricted stock incentive plan, granting 1.44 million shares to 47 eligible participants at a price of RMB 6.86 per share on August 5, 2025 [2][4] - The total funds raised from this incentive plan amount to RMB 9,878,400, which will be used to supplement the company's working capital [6][8] - The effective period of the incentive plan is up to 48 months, with a lock-up period for the granted shares [3][5] Summary by Sections Granting Details - The actual number of restricted shares granted is 1.44 million, with 47 participants involved [4] - The shares were sourced from the company's repurchase of its own A-shares in the secondary market [6] Lock-up and Release Conditions - The lock-up period for the granted shares varies, with specific durations of 12, 24, and 36 months [5] - Shares cannot be transferred or used as collateral until the lock-up conditions are met [5] Financial Impact - The total expense to be recognized for the 1.44 million shares is estimated at RMB 17.38 million, to be amortized over the lock-up period [7] - The incentive plan is expected to positively influence the company's performance, outweighing the costs associated with the plan [7]

Core Viewpoint - The announcement details the approval and implementation of the 2025 Stock Option Incentive Plan by the company, including the number of options granted, the conditions for granting, and the adjustments made to the plan due to changes in the list of eligible participants [2][31]. Summary by Sections Incentive Plan Overview - The 2025 Stock Option Incentive Plan was approved during the company's board meetings held on September 18, 2025, with a total of 15.125 million stock options granted to 621 participants [2][6][31]. - The exercise price for the stock options is set at 37.98 yuan per share [3][16]. Approval Process - The plan underwent several approval steps, including meetings on August 21, September 3, and September 9, 2025, where various related proposals were discussed and approved [9][10][11][32]. - The company conducted a public notice period from August 23 to September 1, 2025, during which no objections were raised regarding the list of incentive participants [10][32]. Adjustments to the Plan - The number of participants was adjusted from 624 to 621, and the total number of stock options granted was reduced from 15.159 million to 15.125 million due to some participants opting out [31][34]. - The adjustments were within the authorized scope and did not require further shareholder approval [34]. Granting Conditions - The granting of stock options is contingent upon the company meeting specific performance criteria over the fiscal years 2025 to 2027, with annual assessments of net profit [7][12]. - Individual performance assessments will also determine the actual number of options that can be exercised by each participant [8][12]. Financial Impact - The funds raised through this incentive plan will be used to supplement the company's working capital [21]. - The company anticipates that the incentive plan will positively influence its financial performance, outweighing the costs associated with the stock options [24][47]. Legal and Advisory Opinions - Legal opinions confirm that the adjustments and the granting of stock options comply with relevant laws and regulations [27][36]. - An independent financial advisor has also validated that the conditions for granting the stock options have been met [38].

拨康视云-B(02592)发布公告，于2025年9月18日，根据首次公开发售后股权激励计划向四名雇员参与者 授出428.42万份受限制股份单位，但须获承授人接纳，方可作实。 ...

（记者 曾健辉） 每经AI快讯，天阳科技9月18日晚间发布公告称，本激励计划拟授予的激励对象总人数共计37人，采取 的激励工具为限制性股票，股票来源为公司从二级市场回购的公司A股普通股股票或/和向激励对象定向 发行的公司A股普通股股票；拟向激励对象授予限制性股票数量不超过约434.65万股，约占本激励计划 草案公告时公司股本总额约4.88亿股的0.89%；限制性股票的授予价格为每股12.08元，即满足归属条件 后，激励对象可以每股12.08元的价格购买公司向激励对象授予的公司A股普通股股票，有效期为自限制 性股票授予之日起至激励对象获授的限制性股票全部归属或作废失效之日止，最长不超过36个月。 每经头条（nbdtoutiao）——"25基点太少，50基点太多"：美联储降息"走钢丝"，"特朗普代言人"投下唯 一反对票 ...

Core Viewpoint - Frontier Biotech (688221) has announced a restricted stock incentive plan for 2025, aiming to attract and retain talent while enhancing the company's core competitiveness and achieving strategic goals [1] Group 1: Incentive Plan Details - The plan includes granting a total of 5 million restricted stocks, with 4.25 million for initial grants and 750,000 reserved, at a price of 8.56 yuan per share [1] - The initial grant will be distributed among 27 employees, representing 8.94% of the total workforce of 302 as of December 31, 2024 [2] - 16 out of the 27 recipients are assessed based on R&D metrics, receiving 3.07 million shares, which accounts for 61.40% of the total shares granted [2] Group 2: Performance Targets - For the first vesting period in 2025, the company must achieve at least one IND application and eight new drug patent applications to meet the 100% vesting requirement [2] - For the second vesting period in 2026, the cumulative targets include five IND applications and 16 new drug patent applications, along with one BD transaction for small nucleic acid drugs [3] - Revenue growth targets are set at a minimum of 10% for 2025 and a cumulative growth of 30% for 2025-2026, based on 2024 revenue [3] Group 3: Focus on Small Nucleic Acid Drugs - The incentive plan emphasizes achieving BD transactions for small nucleic acid drugs, highlighting the company's focus in this area [4] - Frontier Biotech has developed a comprehensive and high-standard development system for small nucleic acid drugs, leveraging internal and external collaborations [4] - The company is advancing multiple drug candidates in various therapeutic areas, including IgA nephropathy and metabolic diseases, all currently in preclinical stages [4] Group 4: Technological Innovations - The company has developed a proprietary siRNA delivery vehicle, ACORDE, which is currently under international patent application [5] - The strategic focus is on innovative drug development and commercialization, marking a critical phase for high-quality business growth [5] - The performance metrics of the incentive plan align with the company's strategic needs and are designed to enhance competitiveness and employee motivation [5]

瑞财经 严明会9月17日，安徽富印新材料股份有限公司(以下简称：富印新材）披露北交所IPO问询回 复，保荐机构民生证券，保荐代表人李守民、田尚清，会计师事务所为中汇会计师事务所。 富印新材成立于2016年，注册资本6808.7万元，公司主要经营精密功能材料的研发、生产、销售和服 务。公司精密功能材料产品广泛应用于智能终端、汽车、家电等领域。 富印新材回复称，涂志兵取得股权激励的背景为：富印有限与深圳市前海钜诚投资咨询有限公司于 2018 年12月签订的《顾问服务协议》，由其作为公司的投融资及IPO辅导顾问，向公司提供投融资及 IPO辅 导顾问服务。 | 海源海汇 | 涂志兵 30.00 | 2021年11月,各方根据 由各方依据附属协议 | 246.6 | | --- | --- | --- | --- | | | | 投资协议及附属协议约 的约定并协商一致按 | | | | 富印参号 136.6667 | 定执行回购。同时,为照原价加年化 12%的 | 1.132.01 | | | | 获取涂志兵及其实际控 收益率确定。 | | 公司本次拟募资4.04亿元，用于精密功能材料生产建设项目(一期)等三大项目以及 ...

Core Viewpoint - Xinjiang Bayi Steel Co., Ltd. announced the repurchase and cancellation of certain restricted stock options due to unmet performance targets and changes in the eligibility of some incentive recipients [1] Group 1: Stock Repurchase Details - The company will repurchase and cancel a total of 5,793,600 shares involving 206 individuals [1] - The repurchase price will be either 3.13 CNY or 3.28 CNY per share, plus interest based on the bank's current term deposit rates [1] - The cancellation is expected to be completed by September 23, resulting in a reduction of the total share capital from 1,538,691,470 shares to 1,532,897,870 shares [1]